Literature DB >> 16421755

Dendritic cell infiltration and prognosis of human hepatocellular carcinoma.

Xiao-Yan Cai1, Qiang Gao, Shuang-Jian Qiu, Sheng-Long Ye, Zhi-Quan Wu, Jia Fan, Zhao-You Tang.   

Abstract

AIM: To elucidate the relationship between local immunocompetent cells and prognosis of human hepatocellular carcinoma (HCC) after resection.
METHODS: HE staining and immunohistochemical study were carried out on specimens from patients underwent surgical resection. Local immunocompetent cells, such as dendritic cells (DCs), memory T cells, CD3+ T lymphocytes and CD8+ T lymphocytes, were counted and their relationships with tumor-free survival rate were analyzed by grouping DCs with the T lymphocytes retrospectively.
RESULTS: The number grade of infiltrating immunocompetent cells in HCC nodules and pericancerous tissues under HE staining had no significant correlation with tumor-free survival time (P=0.054, 0.071, respectively). DCs were mainly among tumor cells, encircling tumor cells with their pseudopodia and were in contact with T lymphocytes. A certain number of DCs in HCC nodules (> or =25/10HPF) statistically correlated to tumor-free survival time (P=0.005), while a certain number of DCs in pericancerous tissues (> or =28/10HPF) had no correlation with tumor-free survival time (P=0.329). The number of memory T cells, CD3+ T lymphocytes and CD8+ T lymphocytes in HCC nodules strongly correlated to tumor-free survival time (P=0.003, 0.005, 0.037, respectively). The tumor-free survival rate curves revealed that the more DCs or together with memory T cells/CD3+ T lymphocytes or that the more CD8+ T lymphocytes were detected in HCC nodules, the better the prognosis would be.
CONCLUSIONS: Marked infiltration of DCs in HCC nodules was closely related to the prognosis of HCC after surgical resection and can be served as a predictive index for recurrence and metastasis of HCC.

Entities:  

Mesh:

Year:  2006        PMID: 16421755     DOI: 10.1007/s00432-006-0075-y

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  36 in total

1.  Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma.

Authors:  T Ninomiya; S M Akbar; T Masumoto; N Horiike; M Onji
Journal:  J Hepatol       Date:  1999-08       Impact factor: 25.083

Review 2.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

3.  Absence of CD83-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma: relevance to hepatocarcinogenesis.

Authors:  S Chen; S M Akbar; K Tanimoto; T Ninomiya; H Iuchi; K Michitaka; N Horiike; M Onji
Journal:  Cancer Lett       Date:  2000-01-01       Impact factor: 8.679

4.  Prognostic significance of mature dendritic cells and factors associated with their accumulation in metastatic liver tumors from colorectal cancer.

Authors:  Shinichi Miyagawa; Junpei Soeda; Satoshi Takagi; Shiroh Miwa; Eri Ichikawa; Terumasa Noike
Journal:  Hum Pathol       Date:  2004-11       Impact factor: 3.466

5.  Infiltration by immunocompetent cells in early stage invasive carcinoma of the uterine cervix: a prognostic study.

Authors:  P B Bethwaite; L J Holloway; A Thornton; B Delahunt
Journal:  Pathology       Date:  1996-11       Impact factor: 5.306

6.  [Changes in the immune function of dendritic cells (DC) derived from HBV-related hepatocellular carcinoma (HCC) patient's peripheral blood monocytes (PBMC) pulsed with tumor antigen].

Authors:  Yong-qiang Wong; Shuang-jian Qiu; Zhao-you Tang; Sheng-long Ye; Yin-kun Liu; Jia Fan; Rui-xia Sun; Yan Zhao
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2005-05

7.  S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival.

Authors:  N A Zeid; H K Muller
Journal:  Pathology       Date:  1993-10       Impact factor: 5.306

8.  Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy.

Authors:  Richard P Ciavarra; Daniel A Holterman; Roy R Brown; Patricia Mangiotti; Nazita Yousefieh; George L Wright; Paul F Schellhammer; W F Glass; Kenneth D Somers
Journal:  J Immunother       Date:  2004 Jan-Feb       Impact factor: 4.456

9.  Immune system versus tumor: shifting the balance in favor of DCs and effective immunity.

Authors:  Howard L Kaufman; Mary L Disis
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

10.  Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.

Authors:  Ping Yu; Youjin Lee; Wenhua Liu; Thomas Krausz; Anita Chong; Hans Schreiber; Yang-Xin Fu
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307

View more
  34 in total

1.  Infiltration of dendritic cells and T lymphocytes predicts favorable outcome in epithelial ovarian cancer.

Authors:  Z Zhang; J Huang; C Zhang; H Yang; H Qiu; J Li; Y Liu; L Qin; L Wang; S Hao; F Zhang; X Wang; B Shan
Journal:  Cancer Gene Ther       Date:  2015-02-27       Impact factor: 5.987

Review 2.  Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity.

Authors:  Caroline Jochems; Jeffrey Schlom
Journal:  Exp Biol Med (Maywood)       Date:  2011-04-12

3.  The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma.

Authors:  Pengyuan Yang; Geoffrey J Markowitz; Xiao-Fan Wang
Journal:  Natl Sci Rev       Date:  2014-07-14       Impact factor: 17.275

4.  Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma.

Authors:  Yang Xu; Venugopal Chenna; Chaoxin Hu; Hai-Xiang Sun; Mehtab Khan; Haibo Bai; Xin-Rong Yang; Qin-Feng Zhu; Yun-Fan Sun; Anirban Maitra; Jia Fan; Robert A Anders
Journal:  Clin Cancer Res       Date:  2011-08-25       Impact factor: 12.531

Review 5.  Trial watch: Dendritic cell-based anticancer therapy.

Authors:  Norma Bloy; Jonathan Pol; Fernando Aranda; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fučíková; Jérôme Galon; Eric Tartour; Radek Spisek; Madhav V Dhodapkar; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

6.  Tumor-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resection.

Authors:  Yi-Wei Li; Shuang-Jian Qiu; Jia Fan; Qiang Gao; Jian Zhou; Yong-Sheng Xiao; Yang Xu; Xiao-Ying Wang; Jian Sun; Xiao-Wu Huang
Journal:  J Cancer Res Clin Oncol       Date:  2008-09-10       Impact factor: 4.553

7.  Recruitment of dendritic cells in human liver with metastases.

Authors:  M Gulubova; I Manolova; G Cirovski; D Sivrev
Journal:  Clin Exp Metastasis       Date:  2008-06-27       Impact factor: 5.150

Review 8.  The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?

Authors:  Marco Puzzoni; Nicola Silvestris; Francesco Leone; Riccardo Giampieri; Luca Faloppi; Laura Demurtas; Emanuela Dell'Aquila; Donatella Marino; Oronzo Brunetti; Silvio Ken Garattini; Elena Ongaro; Giorgio Astara; Laura Orgiano; Giuseppe Aprile; Daniele Santini; Mario Scartozzi
Journal:  Target Oncol       Date:  2016-10       Impact factor: 4.493

9.  Clinical evaluation of systemic and local immune responses in cancer: time for integration.

Authors:  Dmitriy W Gutkin; Michael R Shurin
Journal:  Cancer Immunol Immunother       Date:  2013-10-08       Impact factor: 6.968

10.  CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer.

Authors:  Stephan Roux; Lionel Apetoh; Fanny Chalmin; Sylvain Ladoire; Grégoire Mignot; Pierre-Emmanuel Puig; Gregoire Lauvau; Laurence Zitvogel; François Martin; Bruno Chauffert; Hideo Yagita; Eric Solary; François Ghiringhelli
Journal:  J Clin Invest       Date:  2008-10-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.